We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Merkel Cell Polyomavirus Infection Can Cause Lethal Carcinoma

By LabMedica International staff writers
Posted on 14 Jun 2016
A benign virus normally found in the skin can lead to a type of rare, lethal skin cancer; specifically, infection by the Merkel cell polyomavirus can lead to Merkel cell carcinoma in immune-compromised individuals.

Merkel cell carcinoma, which metastasizes rapidly, is one of the most aggressive skin cancers, with a mortality rate of 33%, exceeding that of melanoma, and a 45% five-year survival rate and given these dire statistics, medical professionals are keen to find better treatments.

The Merkel cell polyomavirus is an abundant virus frequently found on healthy human skin. More...
Excessive exposure to sunlight and ultraviolet radiation, immune suppression, and advanced age are the most important risk factors for Merkel cell carcinoma. Although the exact function of Merkel cells, found in the lower part of the skin epidermis, is unknown, they are thought to be nerve-associated cells involved in light touch sensation.

Scientists at the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PN, USA) have established a new way to investigate this type of oncogenic viral infection and identified a potential therapeutic agent against Merkel cell polyomavirus infection. The team discovered that the activation of special enzymes called matrix metalloproteinases by a cellular signaling pathway involving the WNT and β-catenin proteins stimulate Merkel cell polyomavirus infection.

These enzymes work in wound healing to re-engineer the skin as it heals. For example, if the skin is harmed by excessive sunlight, this stimulates the WNT/β-catenin signaling pathway, which in turn activates the metalloproteinase enzymes to be made. In the wound-healing process, these enzymes react and catalyze the extracellular matrix of affected cells. This could allow viruses to enter the cells of the dermis skin layer. Merkel cell polyomavirus (MCPyV) preferentially infected dermal fibroblasts in human skin.

The study also found that this study also found that the US Food and Drug Administration (FDA, Silver Springs, MD, USA) -approved drug trametinib for melanoma and other cancers blocks viral infection by stopping Merkel cell polyomavirus transcription and replication. Low doses of trametinib wiped out viral infection in the cell culture model developed. In addition, normal control cells were not affected by trametinib, giving hope to the fact that this drug might be able to be used with little side effects for reducing the viral load in immunocompromised patients and the goal of preventing the development of Merkel cell carcinoma.

Wei Liu, PhD, a senior postdoctoral fellow and co-author of the study, said, “Building on this novel cell culture model for Merkel cell polyomavirus infection, we would like to establish an animal model to elucidate the mechanisms by which Merkel cell polyomavirus infection leads to the highly aggressive Merkel cell carcinoma.” The study was published on June 8, 2106 in the journal Cell Host & Microbe.

Related Links:
Perelman School of Medicine at the University of Pennsylvania
US Food and Drug Administration

New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Test Reader
DIA5000
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.